Table 1.
Baseline patient characteristics and the distribution of lymphoma subtypes.
| Factors | Total (n = 51) | R-M (n = 37) | R-MA (n = 14) | p value | |
|---|---|---|---|---|---|
| Age (year) | (median, range) | 60 (27–80) | 62 (27–80) | 56 (41–64) | 0.012 |
| > 60 y | 25 (49.0%) | 23 (62.2%) | 2 (14.3%) | ||
| ≤ 60 y | 26 (51.0%) | 14 (37.8%) | 12 (85.7%) | 0.002 | |
| Gender | Male | 28 (54.9%) | 22 (59.5%) | 6 (42.9%) | |
| Female | 23 (45.1%) | 15 (40.5%) | 8 (57.1) | 0.29 | |
| Multifocal lesions | Yes | 24 (47.1%) | 21 (56.8%) | 3 (21.4%) | |
| No | 27 (52.9%) | 16 (43.2%) | 11 (78.6%) | 0.024 | |
| Deep-brain involvement | Present | 31 (60.8%) | 22 (59.5%) | 9 (64.3%) | |
| Absent | 20 (39.2%) | 15 (40.5%) | 5 (35.7%) | 0.75 | |
| Biopsy type | Surgical | 21 (41.2%) | 15 (40.5%) | 6 (42.9%) | |
| Stereotactic | 30 (58.8%) | 22 (59.5%) | 8 (57.1%) | 0.88 | |
| ECOG score | 1 | 0 (0%) | 0 (0%) | 0 (0%) | |
| 2 | 26 (51.0%) | 17 (45.9%) | 9 (64.3%) | ||
| 3 | 15 (29.4%) | 12 (32.4%) | 3 (21.4%) | ||
| 4 | 10 (19.6%) | 8 (21.6%) | 2 (14.3%) | 0.51 | |
| KPS score | < 70 | 32 (62.7%) | 24 (64.9%) | 8 (57.1%) | |
| ≥ 70 | 19 (37.3%) | 13 (35.1%) | 6 (42.9%) | 0.61 | |
| LDH | Elevated | 7 (13.7%) | 5 (13.5%) | 2 (14.3%) | |
| Normal | 44 (86.3%) | 32 (86.5%) | 12 (85.7%) | 1.00 | |
| CSF protein | Elevated | 22/34 (64.7%) | 16/25 (64.0%) | 6/9 (66.7%) | |
| Normal | 12/34 (35.3%) | 9/25 (36.0%) | 3/9 (33.3%) | 1.00 | |
| C-Myc | Negative | 53.3% | 53.1% | 53.8% | |
| Positive | 46.7% | 46.9% | 46.2% | 0.96 | |
| Bcl-2 | Negative | 34.0% | 35.3% | 30.8% | |
| Positive | 66.0% | 64.7% | 69.2% | 1.00 | |
| Bcl-6 | Negative | 20.4% | 22.2% | 15.4% | |
| Positive | 79.4% | 77.8% | 84.6% | 0.71 | |
| CD10 | Negative | 77.6% | 80.6% | 69.2% | |
| Positive | 122.4% | 19.4% | 30.8% | 0.40 | |
| MUM-1 | Negative | 14.6% | 20% | 0% | |
| Positive | 85.4% | 80% | 100% | 0.17 | |
| Pathology phenotype | Non-GCB | 35/48(72.9%) | 27/35(77.1%) | 8/13(61.5%) | 0.28 |
| GCB | 13/48(27.1%) | 8/35(22.9%) | 5/13(38.5%) | ||
Notes CSF, cerebrospinal fluid; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell-like; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; R-M, combination regimen of high-dose methotrexate and rituximab; R-MA, combination regimen of rituximab, high-dose methotrexate and cytarabine.